A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
RESIST-TB awarded support for compassionate use project from the Firland Foundation
RESIST-TB has been awarded support from the Firland Foundation for a project proposal entitled “Monitoring Compassionate Use of New TB Drugs for MDR-TB and XDR-TB.” The project aims to survey high-burden countries and assess the demand for compassionate use in these areas, identify barriers to access, publicize these barriers, and propose potential ways to increase access. The survey results will be discussed at a meeting to convene manufacturers of new TB drugs, TB program officials, patient advocates and regulators to develop a consensus on how to increase access to compassionate use for new TB drugs. The Firland Foundation website can be accessed here.
Recent News and Announcements
Johnson & Johnson’s affiliate Janssen Pharmaceutica NV (Janssen) has entered into a collaboration with Stichting International Dispensary Association (IDA) which is a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) to facilitate access to the Company’s anti-tuberculosis medicine. More than 130 low- and middle-income countries outside of the United States will now […]
Treatment Action Campaign (TAC) has called upon the South African government to declare tuberculosis a public health emergency. Activists with TAC released a statement at the 4th South Africa TB Conference in Durban on June 10th demanding a halt to drug-resistant tuberculosis. In South Africa, tuberculosis kills at least 148 people and infects approximately 1,400 people […]
Otsuka pharmaceuticals has announced a framework for reviewing requests for compassionate use of delamanid. The drug, which has recently gained European marketing authorization, has been provided to only three patients under compassionate use thus far, including a pediatric extensively drug-resistant tuberculosis patient (detailed here). The announcement comes after advocates have pushed the company to establish a […]
Otsuka pharmaceuticals announced on April 30th that the European commission has approved marketing authorization for delamanid (Deltyba) for treatment of pulmonary multidrug-resistant tuberculosis. The drug has been approved for use in adults when an effective treatment regimen is not available due to resistance or intolerance. Delamanid is still under approval in Japan. See the full Otsuka […]
Just in time for World TB Day, a new study estimating the incidence of TB disease and MDR-TB in children has been published in the Lancet. The study is the first to make these estimates, conducting a systematic review and modeling age-specific regional notification data to conclude that 1,000,000 children developed tuberculosis disease, of whom […]